Just – Evotec Biologics reports that it has expanded its strategic partnership with Sandoz whereby Just – Evotec will receive payments following the early scientific validation of the agreement with further funding tied to achieving development milestones from 2025.

This expanded partnership solidifies Just – Evotec’s commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France, according to Matthias Evers, PhD, CBO of Evotec.

Just – Evotec and Sandoz have been engaged in a multi-year technology partnership aimed at the rapid development and manufacturing of biosimilars.

“We are thrilled to expand our partnership with Sandoz, building on the successes we’ve achieved since the initial launch,” says Evers. “Introducing additional molecules has the potential to enhance access for millions of patients, while commercial manufacturing from Toulouse will ensure the long-term supply of Sandoz’ biosimilar portfolio. This commercial supply aspect also validates our strategy to establish our second J.POD in Toulouse.”

Previous articleIn Microbiome Therapeutics Manufacturing, Winning Extremophile/Additive Combos Found
Next articleSmall-Molecule “Unsilencers” Show Promise against Angelman Syndrome